Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune Inc is well-positioned for future financial growth due to positive clinical results supporting the expansion of its pipeline into additional high-value indications, specifically ulcerative colitis, which could significantly enhance revenue potential. The company's novel molecular structure demonstrates improved efficacy and access, as evidenced by approximately 40% of patients achieving clinically meaningful improvements in related trials. Furthermore, successful outcomes in Phase 2 trials for atopic dermatitis may establish Evommune as a leader in IL-18 therapies, creating substantial long-term commercial opportunities amidst a competitive landscape of established biologics and JAK inhibitors.

Bears say

Evommune Inc’s stock outlook is negatively impacted by the company's potential to achieve peak sales for its pipeline products, EVO756 and EVO301, being hampered by increased competition in the market. Despite demonstrating some efficacy, EVO756 and EVO301 may struggle with slower-than-expected market adoption and face challenges related to patent expirations, which could lead to faster-than-anticipated generic erosion. Furthermore, the potential for medium- to long-term equity dilution poses an additional financial risk that could deter investor confidence.

Evommune Inc (EVMN) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 6 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.